SYBX Synlogic Inc.

1.73
-0.03  -2%
Previous Close 1.76
Open 1.8
Price To Book 0.36
Market Cap 55,793,908
Shares 32,250,814
Volume 185,454
Short Ratio
Av. Daily Volume 402,672
Stock charts supplied by TradingView

NewsSee all news

  1. Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities

    CAMBRIDGE, Mass., March 30, 2020 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic

  2. Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial

  3. Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit

    CAMBRIDGE, Mass., March 11, 2020 /PRNewswire/ -- Synlogic (NASDAQ:SYBX) announced today that Richard Riese, M.D., Ph.D., Synlogic's chief medical officer, will present at the Chardan Microbiome Medicines Summit at

  4. Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast

    CAMBRIDGE, Mass., March 5, 2020 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the

  5. Synlogic Announces Participation in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 18, 2020 /PRNewswire/ -- Synlogic (NASDAQ:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's president and chief executive officer, will participate in the following upcoming

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be delayed due to COVID-19.
SYNB1618
Phenylketonuria (PKU)
Development to be discontinued due to lack of efficacy.
SYNB1020
Cirrhotic patients with elevated ammonia
Phase 1 monotherapy data due 2020 (might be delayed due to COVID-19).
SYNB1891 and atezolizumab
Solid tumors

Latest News

  1. Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities

    CAMBRIDGE, Mass., March 30, 2020 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic

  2. Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial

  3. Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit

    CAMBRIDGE, Mass., March 11, 2020 /PRNewswire/ -- Synlogic (NASDAQ:SYBX) announced today that Richard Riese, M.D., Ph.D., Synlogic's chief medical officer, will present at the Chardan Microbiome Medicines Summit at

  4. Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast

    CAMBRIDGE, Mass., March 5, 2020 /PRNewswire/ -- Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the

  5. Synlogic Announces Participation in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 18, 2020 /PRNewswire/ -- Synlogic (NASDAQ:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's president and chief executive officer, will participate in the following upcoming

  6. Synlogic Appoints Dr. Michael Burgess to its Board of Directors

    CAMBRIDGE, Mass., Jan. 30, 2020 /PRNewswire/ -- Synlogic, Inc., (NASDAQ:SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment

  7. Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs

    – First subject treated in SYNB1891 immuno-oncology study, data from monotherapy arm expected in 2020 – – Expansion of pipeline with new preclinical programs in secondary hyperoxaluria and maple syrup urine disease

  8. Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors

    Dr. Brennan's expertise across multiple therapeutic areas and stages of drug development will prove vital as Cerevance expands its clinical CNS pipeline Cerevance, a clinical stage biopharmaceutical company advancing

  9. Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development

    – Company expects to initiate Phase 2 clinical trial in patients with phenylketonuria in 1H 2020 – Synlogic, Inc. ((

  10. Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference

    Synlogic (NASDAQ:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's president and chief executive officer, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference at

  11. Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results

    –SYNB1618 solid oral bridging study ongoing and SYNB1891 immuno-oncology study open – – Company ends 3Q2019 with approximately $139 million in cash, cash equivalents and investments supporting projected runway through

  12. Synlogic Announces Third Quarter 2019 Conference Call and Webcast

    Synlogic, Inc. ((

  13. Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference

    Synlogic, Inc. (NASDAQ:SYBX) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's president and chief executive officer, will provide a corporate update at the Chardan 3rd Annual Genetic Medicines Conference on

  14. Synlogic Announces Appointments of New CMO, Head of Regulatory Affairs, and CFO Departure

    Synlogic, Inc. (NASDAQ:SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the following two new additions to its senior leadership

  15. Synlogic Presents Data from Phase 1/2a Study of SYNB1618 at the Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM)

    – Advancing clinical development of SYNB1618 as a novel therapy to potentially serve all patients with phenylketonuria – – Synlogic has initiated a bridging study of a new solid formulation of SYNB1618 to inform